

Edgar Filing: TIMBERLAND BANCORP INC - Form 8-K

TIMBERLAND BANCORP INC
Form 8-K
April 28, 2011

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 26, 2011

Timberland Bancorp, Inc.
(Exact name of registrant as specified in its charter)

Washington	0-23333	91-1863696
-----	-----	-----
State or other jurisdiction Of incorporation	Commission File Number	(I.R.S. Employer Identification No.)

624 Simpson Avenue, Hoquiam, Washington	98550
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number (including area code) (360) 533-4747

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4)

Item 2.02 Results of Operations and Financial Condition

On April 26, 2011, Timberland Bancorp, Inc. issued its earnings release

Edgar Filing: TIMBERLAND BANCORP INC - Form 8-K

for the quarter ended March 31, 2011. A copy of the earnings release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is being furnished herewith and this list shall constitute the exhibit index:

99.1 Press Release of Timberland Bancorp, Inc. dated April 26, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

TIMBERLAND BANCORP, INC.

DATE: April 26, 2011

By: /s/ Dean J. Brydon

Dean J. Brydon
Chief Financial Officer

t Times New Roman, Times, Serif; margin: Opt 0; text-indent: 0.5in">

From 2006 to 2013, Mr. Steinhart, 56, was an executive at MELA Sciences, Inc., most recently serving as its CFO, Senior Vice President, Treasurer and Secretary. From 1992 to 2006, Mr. Steinhart was Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and CFO at Emisphere Technologies from 1991 to 1992 and as General Partner and CFO of CW Group Inc. Mr. Steinhart is a Member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee and a member of the Compensation Committee. From 2004 to 2012, Mr. Steinhart was a Member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee.

In connection with his appointment to the Board, on March 1, 2014 Mr. Steinhart received a restricted stock award of \$50,000 worth of shares of the Company's common stock, or 22,728 shares, under the Company's 2010 Stock Option and Incentive Plan (the "Plan"), which vests quarterly over one year from the date of grant. In connection with Mr. Steinhart's service on the Board through the 2014 annual meeting of stockholders, he was granted an option to purchase 16,484 shares of the Company's common stock under the Plan, exercisable at \$2.20 per share, which was the fair market value on the date of grant. The option vests and becomes exercisable at the 2014 annual meeting of stockholders. Mr. Steinhart will also receive the cash compensation payable to non-employee directors for attendance

at board meetings pursuant to the Company's non-employee director compensation policy. The Company has entered into its standard form of indemnification agreement with Mr. Steinhart.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ATOSSA GENETICS INC.

Date: March 5, 2014

By: /s/ Kyle Guse
Kyle Guse
Chief Financial
Officer, General
Counsel and
Secretary